has signed an agreement to purchase a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed amount.
PCSK9 is a protein that modulates the low-density lipoprotein (LDL) or 鈥榖ad鈥� cholesterol levels in the blood. Increased PCSK9 activity results in high LDL cholesterol.
The PCSK9 inhibitors covered under this agreement are small molecules designed to attach to a new part of PCSK9. In preclinical models, these PCSK9 inhibitors blocked its activity and lower LDL cholesterol.
Speaking of the development with AstraZeneca, Dogma Therapeutics CEO Brian Hubbard said: 鈥淲e have built a robust data package that highlights the cholesterol-lowering and safety potential of our oral PCSK9 programme.
鈥淭his agreement with AstraZeneca meets our strategic goal to accelerate access to patients unable to meet target LDL cholesterol.鈥�
AstraZeneca plans to advance the acquired programme into clinical development for dyslipidaemia, characterised by an abnormal amount of lipids in the blood.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, the company will focus on development in familial hypercholesterolemia, a common genetic condition that leads to high cholesterol.
Currently, there are no oral PCSK9 inhibitors approved for patient use or in clinical development.
AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: 鈥淲hilst PCSK9 is a well-validated target for lowering LDL cholesterol, it has been a hugely challenging target to inhibit with small molecules.
鈥淭his agreement with Dogma Therapeutics offers us the opportunity to develop the first small molecule, orally bioavailable PCSK9 inhibitor, for patients at risk of cardiovascular disease.鈥�
Pangalos added that increased LDL cholesterol is a significant risk factor for cardiovascular disease. Statistics show that the condition is responsible for 2.6 million deaths per year, globally.
AstraZeneca expects to begin clinical development of the PCSK9 inhibitors next year.
Last month, AstraZeneca entered an agreement with UK-based biotechnology company Redx Pharma to license a porcupine inhibitor, RXC006, for fibrotic diseases.
